摘要
目的探讨康莱特注射液联合介入化疗栓塞治疗中、晚期原发性肝癌的疗效。方法本组共80例肝癌患者,采用随机对照方法分两组,治疗组(康莱特+介入化疗栓塞)与对照组(单纯介入化疗栓塞)各40例。观察临床症状变化、Karnofsky评分、血生化指标及近期疗效,对临床资料进行分析。结果在临床症状改善、抑制肿瘤瘤体生长、体重增加、Karnofsky评分提高、减轻介入化疗骨髓抑制毒性反应(白细胞、血小板下降)和增加方面,治疗组明显优于对照组(P<0.05),而在血红蛋白下降、肝功能损害、恶心、呕吐方面两组差异无统计学意义(P>0.05)。结论临床观察表明,康莱特在中、晚期肝癌介入治疗中能明显改善患者生存质量,减轻化疗栓塞后毒副反应,在提高综合疗效方面效果肯定,值得临床推广应用。
Objective To evaluate the efficacy of KanLaite injection combined with chemoembolization on primary middle and advanced stage liver cancer. Methods Eighty patients were at random divided into two groups. Forty patients in treatment group were treated with Kanlaite injection combined with chemoembolization. The other forty patients in control group were treated with chemoembolization. Results The treatment group was significantly superior to the control group in improving clinical symptoms, control tumor growing, gaining weight, increasing KPS and relieving sideeffect of chemotherapy in marrow toxicity（ P 〈 0.05）. But in haemachrome reduce, liver function damage, nausea and vomiting, the treatment group was not significantly superior to the control group（ P 〉 0.05）. Conclusions Kanlaite injection had obvious effect on improving the patients＇ living quality and relieving side effect after chemoembolization, Kanlaite injection should be popularized during primary middle and advanced stage liver cancer.
出处
《肿瘤基础与临床》
2006年第2期132-134,共3页
journal of basic and clinical oncology
